Compass Therapeutics, Inc. Common Stock (CMPX)
Compass Therapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for cancer and other diseases. The company utilizes proprietary platform technologies to discover and develop monoclonal antibodies and other biologics aimed at modulating the immune system to combat chronic diseases.
Company News
Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.
Compass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.
Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.